A new study found that continuous glucose monitors can cut healthcare costs by about 20% while also improving outcomes for insulin-dependent diabetes patients, largely by reducing hospitalizations and emergency department visits. Despite these benefits and broad insurance coverage, roughly 80% of eligible patients still are not using the technology — highlighting a significant adoption gap.
Over-the-counter continuous glucose monitors have been available for people with and without diabetes for more than a year now — but the data they collect doesn’t seem to be as useful for nondiabetic users, according to new research from Mass General Brigham.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, consumer-oriented segment of its business, while also giving the diabetes unit more room to focus and compete in its own crowded market.
Dexcom recently became the first medical device company to embed generative AI into a continuous glucose monitor. Adding generative AI to the company’s Stelo glucose monitor will give users more personalized recommendations about how to improve their metabolic health, said Dexcom COO Jake Leach.
This week at HLTH, Dexcom COO Jake Leach discussed Stelo, his company's new product. Stelo is an over-the-counter continuous glucose monitor meant for all adults who don't take insulin.
Continuous Glucose Monitoring tools are revolutionizing the way diabetes is managed, offering unparalleled benefits for both healthcare providers and patients. By providing continuous, accurate data, CGM is especially useful for remote monitoring, enabling timely interventions and leading to better user health.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Now more than ever, enhancing primary care practices to include CGM capabilities is a crucial goal requiring the support and involvement of the broader healthcare community.
Oura — a company selling a ring that tracks peoples’ biometrics — announced new partnerships with three providers of continuous glucose monitors: January, Supersapiens and Veri. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users’ glucose levels and overall health.
In July, Dexcom got FDA clearance to allow third parties to access its CGM data. To start, it is integrating with Garmin’s wearable devices.
Graphwear recently raised $20.5 million, which it plans to use to develop a CGM that uses nanotechnology to measure blood glucose levels.
How to turn analytics into actual policy outcomes.